Merck: J.P. Morgan Healthcare Conference (Merck (MSD)) - Jan 18, 2016 - Anticipated completion of P2b trial (NCT02332707) of MK-3682 + grazoprevir + elbasvir/MK-8408 for chronic hepatitis C infection in 2016; Anticipated completion of P2b trial (NCT02332720) of MK-3682 + grazoprevir + elbasvir/MK-8408 for chronic hepatitis C infection in 2016; Anticipated initiation of P3 trial of MK-3682 + grazprevir + elbasvir in hepatitis C infection in 2016
Anticipated new P3 trial • Anticipated trial completion date • Hepatitis C Virus
|